King Sallyann Coleman, Pollack Lori A, Li Jun, King Jessica B, Master Viraj A
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Department of Urology and Winship Cancer Institute, School of Medicine, Emory University (VAM), Atlanta, Georgia.
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Department of Urology and Winship Cancer Institute, School of Medicine, Emory University (VAM), Atlanta, Georgia.
J Urol. 2014 Jun;191(6):1665-70. doi: 10.1016/j.juro.2013.12.046. Epub 2014 Jan 11.
More than 50,000 Americans were diagnosed with kidney and renal pelvis cancer in 2010. The National Program of Cancer Registries and SEER (Surveillance, Epidemiology and End Results) combined data include cancer incidences from the entire United States. Our study presents updated incidence data, evaluates trends and adds geographic distribution to the literature.
We examined invasive, microscopically confirmed kidney and renal pelvis cancers diagnosed from 2001 to 2010 that met United States Cancer Statistics reporting criteria for each year, excluding cases diagnosed by autopsy or death certificate. Histology codes classified cases as renal cell carcinoma. Rates and trends were estimated using SEER∗Stat.
A total of 342,501 renal cell carcinoma cases were diagnosed. The renal cell carcinoma incidence rate increased from 10.6/100,000 individuals in 2001 to 12.4/100,000 in 2010 and increased with age until ages 70 to 74 years. The incidence rate in men was almost double that in women. The annual percent change was higher in women than in men, in those 20 to 24 years old and in grade III tumors.
The annual percent change incidence increased from 2001 to 2010. Asian/Pacific Islanders and 20 to 24-year-old individuals had the highest annual percent change. While some increase resulted from localized disease, the highest annual percent change was in grade III tumors, indicating more aggressive disease. Continued monitoring of trends and epidemiological study are warranted to determine risk factors.
2010年，超过5万名美国人被诊断患有肾癌和肾盂癌。国家癌症登记计划和监测、流行病学及最终结果（SEER）联合数据涵盖了美国全国的癌症发病率。我们的研究提供了最新的发病率数据，评估了趋势，并补充了文献中的地理分布信息。
我们研究了2001年至2010年期间诊断出的、经显微镜确诊的侵袭性肾癌和肾盂癌，这些病例符合每年美国癌症统计报告标准，不包括通过尸检或死亡证明诊断的病例。组织学编码将病例分类为肾细胞癌。发病率和趋势使用SEER∗Stat进行估计。
共诊断出342,501例肾细胞癌病例。肾细胞癌发病率从2001年的10.6/10万上升至2010年的12.4/10万，并随年龄增长至70至74岁。男性发病率几乎是女性的两倍。20至24岁女性以及III级肿瘤患者的年变化百分比高于男性。
2001年至2010年，年变化百分比发病率上升。亚洲/太平洋岛民以及20至24岁人群的年变化百分比最高。虽然部分增长源于局限性疾病，但年变化百分比最高的是III级肿瘤，表明疾病更具侵袭性。有必要持续监测趋势并开展流行病学研究以确定风险因素。
